Navigation Links
Gene Mutations May Blunt Plavix's Effectiveness, Study Finds
Date:10/26/2010

By Steven Reinberg
HealthDay Reporter

TUESDAY, Oct. 26 (HealthDay News) -- People with certain gene variants who take the blood-thinning drug Plavix (clopidogrel) may be at increased risk for serious complications after coronary stent placement, a new study finds.

Having the gene variants seems to reduce the effectiveness of Plavix and put patients at higher risk of developing blood clots in the stent, suffering a heart attack or stroke, or even dying, according to the research.

"Clopidogrel is one of the most commonly prescribed medications worldwide," said lead researcher Dr. Jessica L. Mega, an instructor in medicine at Brigham and Women's Hospital and Harvard Medical School in Boston.

But, "not all patients experience the same anti-clotting effects of the medication. Some of this variation is based on genetic variants in the CYP2C19 gene," she said.

For the study, published in the Oct. 27 issue of the Journal of the American Medical Association, Mega's team conducted a meta-analysis of nine studies involving a total of 9,685 people. In a meta-analysis, researchers review published studies to tease out data about particular outcomes.

In this case, the researchers looked for the effect that variants of the CYP2C19 gene had on people taking the antiplatelet drug and undergoing angioplasty and stent placement to open a blocked artery.

Among the patients studied, 863 died or had a heart attack or stroke, and 84 developed blood clots in their stents.

The researchers found that 71.5 percent of the total patient group had no variant of the CYP2C19 gene. However, 26.3 percent had one variant and 2.2 percent had two variants of the CYP2C19 gene that appeared to affect the body's response to Plavix.

Having one or two variants significantly increased the risk of death, heart attack or stroke, or developing blood clots in the stents, the researchers found.

Plavix uses a liver enzyme to convert the drug to its active form. The genetic variants prevent all of the drug from being converted, which increases the odds of poorer outcomes.

The study was limited, however, in that 95.8 percent of the patients studied were white and individual patient-level data from the studies could not be combined, researchers noted.

Last March, the U.S. Food and Drug Administration said Plavix must carry a "black box" warning on its label, alerting patients and doctors that some people don't metabolize the medication properly.

"Almost one in three patients is not receiving ideal protection from ischemic events when treated with standard doses of clopidogrel for coronary stenting," Mega said.

"Given how widely clopidogrel is used to treat patients with cardiovascular disease, determination of the optimal antiplatelet treatment doses or regimens for individual patients is needed to tailor therapy appropriately," she added.

The findings raise the question of whether routine genetic testing of Plavix patients is needed, but some experts say it's too early for that.

Dr. Gregg Fonarow, an American Heart Association spokesman and professor of cardiology at the University of California, Los Angeles, noted that a clinical alert issued in July by the American College of Cardiology and American Heart stated that "the evidence base is insufficient to recommend routine genetic testing at the present time in clopidogrel-treated patients."

"There is no information that routine testing improves outcome in large subgroups of patients," Fonarow said. "Further studies are needed to determine if routine genetic testing or platelet function testing and alteration of the antiplatelet regimen based on these findings will improve clinical outcomes."

Another expert, Dr. Valentin Fuster, a professor at Mount Sinai School of Medicine in New York City and author of an accompanying journal article, agrees that genetic testing isn't necessary.

"It's very nice that we learn about genetics, but to have a clinical applicability to the patient is still very far off," he said.

More information

For more information on Plavix, visit the U.S. Food and Drug Administration.

SOURCES: Jessica L. Mega, M.D., M.P.H., instructor in medicine, Brigham and Women's Hospital and Harvard Medical School, Boston; Valentin Fuster, M.D., Ph.D., the Richard Gorlin, MD/Heart Research Foundation Professor, Mount Sinai School of Medicine, New York City; Gregg Fonarow, M.D., American Heart Association spokesman and professor, cardiology, University of California, Los Angeles; Oct. 27, 2010, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene Mutations Identified for Charcot-Marie-Tooth Syndrome
2. Study shows that mutations in 1 gene cause many cancers
3. Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast
4. Gene Mutations Up Risk for Cancer in Opposite Breast
5. Heart Disease Among Childhood Cancer Survivors Tied to Gene Mutations
6. Single Lung Tumor Contains 50,000 Mutations
7. Gene Mutations Offer Clues to Autoimmune Disorders
8. Individual mutations are very slow to promote tumor growth
9. Study finds women with triple negative breast cancer and BRCA mutations have lower risk of recurrence
10. Emotions May Be Blunted in Alzheimers Patients
11. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Mutations May Blunt Plavix's Effectiveness, Study Finds
(Date:2/23/2017)... ... February 23, 2017 , ... On ... issued a letter to withdraw previous guidance issued by the Obama ... The guidance issued in May 2016 by the Obama Administration came in response ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial ... 74th Annual Meeting. KLS is a longtime supporter of the event. , "We ... and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, ... a raffle. Throughout the month of February, patients who visit Hamlin Dental Group will ... a dinner for two at the Cheesecake Factory. , Tickets are available for ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the Cowen and Company 37 th Annual Health ... Tuesday, March 7, 2017 at 11:20 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/cowen38/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/24/2017)... CUPERTINO, Calif. , Feb. 24, 2017  In ... fourth quarter 2016 financial results press release, you are ... be broadcast live over the internet on Tuesday, March ... Pacific Time). A live audio webcast of ... at www.durect.com and clicking "Investor Relations."  If ...
(Date:2/24/2017)... , Australien, 24. Februar 2017 ... diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für das ... mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu ... und Aktualisierung zum Wachstum" finden Sie hier ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; ...
Breaking Medicine Technology: